Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555667 | 0.83 | GRIK1 (0.33) | FAAH | |
| SCHEMBL28726944 | 0.83 | — | — | |
| SCHEMBL28159126 | 0.83 | — | — | |
| SCHEMBL28317076 | 0.80 | SLC1A2 (0.41) | FAAH | |
| SCHEMBL28393898 | 0.80 | CETP (0.32) | — | |
| SCHEMBL20479435 | 0.79 | — | — | |
| SCHEMBL7710333 | 0.79 | — | — | |
| SCHEMBL3424225 | 0.79 | SLC7A5 (0.39) | — | |
| SCHEMBL2263113 | 0.79 | — | — | |
| SCHEMBL2158216 | 0.79 | GRIK1 (0.42) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114395117-A | Double-end perfluoropolyether and preparation method thereof | 西安近代化学研究所 | 2022-04-26 | — | — | CN | claimed |
| WO-1996020592-A1 | METHOD FOR INACTIVATING NON-ENVELOPED VIRUSES USING A VIRICIDE-POTENTIATING AGENT | HEMASURE INC. (US) | 1996-07-11 | — | — | WO | claimed |
| US-12600971-B2 | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence | BEAM THERAPEUTICS INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260083861-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING CD70 EXPRESSION | EDITAS MEDICINE, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260054197-A1 | SYSTEM FOR RECOVERING ANTIGEN IN SOLVENT AND METHOD FOR RECOVERING ANTIGEN IN SOLVENT | GOGEN TECH LTD (JP) | 2026-02-26 | — | — | US | disclosed |
| US-12545912-B2 | CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa | EDITAS MEDICINE, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260002159-A1 | METHODS, COMPOSITIONS AND COMPONENTS FOR CRISPR-CAS9 EDITING OF CBLB IN T CELLS FOR IMMUNOTHERAPY | EDITAS MEDICINE INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12435120-B2 | Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods | JUNO THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250297287-A1 | COMPOSITIONS AND METHODS FOR GENOME EDITING THE NEONATAL FC RECEPTOR | APELLIS PHARMACEUTICALS, INC. (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250288698-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HOMOLOGY DIRECTED REPAIR | EDITAS MEDICINE, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250249099-A1 | COMPOSITIONS FOR CELL-SPECIFIC EXPRESSION AND USES THEREOF | CREATE MEDICINES, INC. | 2025-08-07 | — | — | US | disclosed |
| EP-0923284-A4 | CELLULAR IMMUNOGENS USEFUL AS CANCER VACCINES | ALLEGHENY UNIVERSITY OF THE HE (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-1242609-A2 | NOVEL COLLOID SYNTHETIC VECTORS FOR GENE THERAPY | Novartis AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049324-A2 | NOVEL COLLOID SYNTHETIC VECTORS FOR GENE THERAPY | NOVARTIS AG (CH) | 2001-07-12 | — | — | WO | disclosed |
| EP-0783482-A4 | CATIONIC TRANSPORT REAGENTS | UNIV CALIFORNIA (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0923284-A1 | CELLULAR IMMUNOGENS USEFUL AS CANCER VACCINES | Allegheny University of The Health Sciences (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1997025860-A1 | CELLULAR IMMUNOGENS USEFUL AS CANCER VACCINES | ALLEGHENY UNIVERSITY OF THE HEALTH SCIENCES (US) | 1997-07-24 | — | — | WO | disclosed |
| EP-0783482-A1 | CATIONIC TRANSPORT REAGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010555-A9 | CATIONIC TRANSPORT REAGENTS | — | 1996-06-13 | — | — | WO | disclosed |
| WO-1996010555-A1 | CATIONIC TRANSPORT REAGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545912-B2 | CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa | UPF1, RPRD2, NR2E3 | FAAH 3223/4885 |
| US-12600971-B2 | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence | CDA, ADAR, ADA | FAAH 4253/4885 |
| US-20250288698-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HOMOLOGY DIRECTED REPAIR | MRE11, DCLRE1A, RAD51 | FAAH 4146/4885 |
| US-20260083861-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS TARGETING CD70 EXPRESSION | CD74, CD2, CD4 | FAAH 4882/4885 |
| US-20260002159-A1 | METHODS, COMPOSITIONS AND COMPONENTS FOR CRISPR-CAS9 EDITING OF CBLB IN T CELLS FOR IMMUNOTHERAPY | CBLB, CBL, BCL9L | FAAH 4834/4885 |
| US-20260054197-A1 | SYSTEM FOR RECOVERING ANTIGEN IN SOLVENT AND METHOD FOR RECOVERING ANTIGEN IN SOLVENT | CD14, CD44, CETP | FAAH 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.